Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Steven M. Horwitz, Reinhard Dummer, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Jose A. Sanches, Pablo L. Ortiz-Romero, Oleg E. Akilov, Larisa Geskin, Judith Trotman, Kerry Taylor, Stephane Dalle, Michael Weichenthal, Jan Walewski, David Fisher, Brigitte Dréno, Rudolf StadlerTatyana Feldman, Timothy M. Kuzel, Yinghui Wang, Maria Corinna Palanca-Wessels, Erin Zagadailov, William L. Trepicchio, Wenwen Zhang, Hui Min Lin, Yi Liu, Dirk Huebner, Meredith Little, Sean Whittaker, Madeleine Duvic, David Joske, Ian D. Lewis, Constanze Jonak, Franz Trautinger, Oliver Bechter, Dominique Bron, Vladmir Claudio C. de Lima, Richard Klasa, Martine Bagot, Marie Beylot-Barry, Michel D'Incan, Brigitte Dreno, Florent Grange, Jan Nicolay, Marion Wobser, Chalid Assaf, Carmen Loquai, Michele Spina, Alberto Bosi, Pier Paolo Fattori, Aleksandra Grzanka, Andres Lopez-Hernandez, Jose Juan Rifon Roca, Silvana Novelli Canales, Timothy Illidge, Rod Johnson, Stephen Morris, Pam McKay, Barbara Pro, Adam Lerner, Herbert Eradat, Lubomir Sokol, Sarah Hughey

Research output: Contribution to journal › Article › peer-review

435 Scopus citations

Fingerprint

Dive into the research topics of 'Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial'. Together they form a unique fingerprint.

Medicine & Life Sciences